English | 繁體

Search in the results

UM

Browse/Search Results:  1-6 of 6 Help

Selected(0)Clear Items/Page:    Sort:
A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov Journal article
Yang, Jing, Kang, Heming, Lyu, Liyang, Xiong, Wei, Hu, Yuanjia. A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov[J]. Discover Oncology, 2023, 14(1), 151.
Authors:  Yang, Jing;  Kang, Heming;  Lyu, Liyang;  Xiong, Wei;  Hu, Yuanjia
Favorite | TC[WOS]:7 TC[Scopus]:7 | Submit date：2023/09/21
Bispecific Antibodies  Combination Therapy  Immuno-oncology Therapy  Kinase Inhibitors  Pd-1/pd-l1 Inhibitors  Targeted Therapy  
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives Journal article
Ye,Zi Han, Yu,Wei Bang, Huang,Mu Yang, Chen,Jun, Lu,Jin Jian. Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives[J]. Acta Pharmaceutica Sinica B, 2023, 13(4), 1467-1487.
Authors:  Ye,Zi Han;  Yu,Wei Bang;  Huang,Mu Yang;  Chen,Jun;  Lu,Jin Jian
Favorite | TC[WOS]:9 TC[Scopus]:10  IF:14.7/14.1 | Submit date：2023/08/03
Bispecific Antibodies  Cancer  Cd47  Clinical Data  Combination Strategies  Future Perspectives  Mechanisms  Preclinical Data  
Building on the backbone of CD47-based therapy in cancer: Combination strategies, mechanisms, and future perspectives Review article
2023
Authors:  Ye, Zi Han;  Yu, Wei Bang;  Huang, Mu Yang;  Chen, Jun;  Lu, Jin Jian
Favorite | TC[WOS]:9 TC[Scopus]:10  IF:14.7/14.1 | Submit date：2023/05/02
Bispecific Antibodies  Cancer  Cd47  Clinical Data  Combination Strategies  Future Perspectives  Mechanisms  Preclinical Data  
A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques Journal article
Feng, Y., Zhao, Q., Chen, W., Wang, Y., Crowder, K., Dimitrov, D.. A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaques[J]. Experimental and molecular pathology, 2014, 359-367.
Authors:  Feng, Y.;  Zhao, Q.;  Chen, W.;  Wang, Y.;  Crowder, K.; et al.
Favorite |   IF:2.8/2.7 | Submit date：2023/08/30
Bispecific antibodies  Cynomolgus macaques  Half-life  IGF ligand.  
A new bispecific antibody targeting non-overlapping epitopes on IGF2: Design, in vitro characterization and pharmacokinetics in macaques Journal article
Feng Y., Zhao Q., Chen W., Wang Y., Crowder K., Dimitrov D.S.. A new bispecific antibody targeting non-overlapping epitopes on IGF2: Design, in vitro characterization and pharmacokinetics in macaques[J]. Experimental and Molecular Pathology, 2014, 97(3), 359-367.
Authors:  Feng Y.;  Zhao Q.;  Chen W.;  Wang Y.;  Crowder K.; et al.
Favorite | TC[WOS]:14 TC[Scopus]:14 | Submit date：2019/01/16
Bispecific Antibodies  Cynomolgus Macaques  Half-life  Igf Ligand  
Soluble expression, purification and bioactivity assay of anti-ovarian carcinoma x anti-CD3 x anti-CD28VH single chain trispecific antibody Journal article
Zhao, B., Wang, X., Zhao, Q., Wang, S., Huang, H.. Soluble expression, purification and bioactivity assay of anti-ovarian carcinoma x anti-CD3 x anti-CD28VH single chain trispecific antibody[J]. Chinese Journal of Microbiology and Immunology, 2004, 475-479.
Authors:  Zhao, B.;  Wang, X.;  Zhao, Q.;  Wang, S.;  Huang, H.
Favorite |  | Submit date：2023/08/30
Bispecific Antibodies  Blinatumomab  Single Chain Fragment Variable Antibody